Das polyzystische Ovarsyndrom

Das polyzystische Ovarsyndrom (PCOS) ist die häufigste hormonelle Störung bei Frauen im fertilen Lebensalter. In der Schwangerenvorsorge wird ihm trotz möglicher Auswirkungen auf Mutter und Fetus häufig wenig Aufmerksamkeit geschenkt. Dabei ist eine frühe Diagnose unverzichtbar, um Schwangerschafts- und Langzeitkomplikationen zu vermeiden bzw. zu reduzieren. Der Artikel vermittelt, was Hebammen über die Diagnostik, pathophysiologische Prozesse, bisherige Behandlungsmöglichkeiten und potenzielle Schwangerschaftskomplikationen bei Frauen mit PCOS wissen sollten.

Publication History

Article published online:
13 May 2025

• Literatur

• 1 Farland LV, Stern JE, Liu CL. et al. Polycystic ovary syndrome and risk of adverse pregnancy outcomes: a registry linkage study from Massachusetts. Hum Reprod 2022; 37: 2690-2699
• 2 Franik S, Le QK, Kremer JA. et al. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2022; 9: CD010287
• 3 Huddleston HG, Dokras A. Diagnosis and Treatment of Polycystic Ovary Syndrome. JAMA 2022; 327: 274-275
• 4 Ibáñez L, Oberfield SE, Witchel S. et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr 2017; 88: 371-395
• 5 Lim SS, Kakoly NS, Tan JWJ. et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev 2019; 20: 339-352
• 6 Mills G, Badeghiesh A, Suarthana E. et al. Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies. Hum Reprod 2020; 35: 1666-1674
• 7 Moran LJ, Ko H, Misso M. et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. Hum Reprod 2013; Update 2013 19: 432-432
• 8 Naver KV, Grinsted J, Larsen SO. et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG 2014; 121: 575-581
• 9 Nguyen AT, Curtis KM, Tepper NK. et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep 2024; 73: 1-126
• 10 Persson S, Elenis E, Turkmen S. et al. Fecundity among women with polycystic ovary syndrome (PCOS) – a population-based study. Hum Reprod 2019; 34: 2052-2060
• 11 Rowan JA, Rush EC, Plank LD. et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Res Care 2018; 6: e000456
• 12 Schäfer-Graf U, Reger-Tan S. PCOS und Schwangerschaft. Gynäkologe 2022; 55: 85-89
• 13 Sonntag B. Endokrinologie und Reproduktion: Das Polyzystische Ovarialsyndrom ist mehr als nur eine Zyklusstörung. Dtsch Arztebl International. 2023 120. A-1780
• 14 Teede H, Tay CT, Laven JSE. et al. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University. Online resource Im Internet https://bridges.monash.edu/articles/online_resource/International_Evidence-based_Guideline_for_the_Assessment_and_Management_of_Polycystic_Ovary_Syndrome_2023/24003834
• 15 Thannickal A, Brutocao C, Alsawas M. et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2020; 92: 338-349
• 16 Zhang J, Xu JH, Qu QQ. et al. Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies. Front Cardiovasc Med 2020; 7: 552421
• 17 Zhao H, Zhang J, Cheng X. et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res 2023; 16: 9